Farxiga
(Dapagliflozin)ApprovedSmall molecule
AstraZenecaDapagliflozin is used to treat type 2 diabetes by helping the kidneys remove excess sugar through urine, and it's also used to treat heart failure and chronic kidney disease to reduce the risk of hospitalization and death.[2] Farxiga is currently approved and in use across 99 indications[4].[1]
Farxiga is one of 1740 small molecule programs targeting Insulin resistance. It is currently in Approved.
99
Indications
513
Total Trials
38
Active Trials
1,739
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
22
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 97 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Farxiga
AstraZenecaApproved
Halaven
EisaiPreclinical
Gemzar
GGynecologic Oncology Group
Preclinical
Megace
Bristol-Myers SquibbPreclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Tricor
JJagotec
Preclinical
Vfend
PPrism Pharmaceuticals
Preclinical
Zoladex
Luye Pharma Group Ltd.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Dapagliflozin44 trials
Show 41 more trials
Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria
Completed·TThe University of Texas Health Science Center at San Antonio·Phase 4·NCT03331289·107 enrolled
Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients
Unknown status·—·Phase 4·NCT05225077·600 enrolled
Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin
Completed·TThe University of Texas Health Science Center at San Antonio·Phase 3·NCT02984644·30 enrolled
Type 2 Diabetes32 trials
A Study Between Dapagliflozin and Empagliflozin Effect on NAFLD in Patients With Type 2 Diabetes.
Completed·—·Phase 4·NCT07363707·108 enrolled
Show 29 more trials
Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
Active, not recruiting·FFundación para la Investigación del Hospital Clínico de Valencia·Phase 4·NCT06851962·504 enrolled
Type 2 Diabetes Mellitus14 trials
Dapagliflozin vs Empagliflozin on Flow Mediated Dilation in Type 2 Diabetes Mellitus
Unknown status·CCentro Universitario de Ciencias de la Salud, Mexico·Phase 3·NCT04195243·24 enrolled
Show 11 more trials
Dapagliflozin Versus Glimepiride Effect in Patient With Type 2 Diabetes Mellitus
Completed·—··NCT04240171·60 enrolled
A Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI)
Not yet recruiting·—·Phase 4·NCT07311551·112 enrolled
Heart Failure12 trials
Show 9 more trials
Dapa Acute Heart Failure Study
Unknown status·—··NCT05759000·100 enrolled
Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy
Completed·—·Phase 4·NCT04575675·78 enrolled
Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure
Recruiting·FFundación para la Investigación del Hospital Clínico de Valencia·Phase 4·NCT06578520·31 enrolled
Effect of Dapagliflozin on VT in Patients With Heart Failure.
Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 4·NCT05550441·120 enrolled
SGLT2-Inhibitors for Sleep Apnea in Heart Failure
Withdrawn·—·Phase 2·NCT04640493
Chronic Kidney Disease7 trials
Efficacy and Safety of Dapagliflozin in Children With Proteinuric Chronic Kidney Disease
Withdrawn·—·Phase 4·NCT04531397
Show 4 more trials
Dapaglifozin to Avoid Acute Kindey Injury (AKI) to Chronic Kidney Disease (CKD) Transition: DAKI-CKD Study
Recruiting·IInstituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran·Phase 2/3·NCT05713851·100 enrolled
Replication of the DAPA-CKD (Chronic Kidney Disease) Trial in Healthcare Claims Data
Completed·—··NCT04882813·87,727 enrolled
60 more indications
Type 1 Diabetes7 trials
Atrial Fibrillation6 trials
Efficacy of Dapagliflozin on Recurrence After Catheter Ablation for Atrial Fibrillation
Completed·—·N/A·NCT06433479·200 enrolled
Show 3 more trials
Type 2 Diabetic Patients5 trials
Effect of the Antidiabetic Drug Dapagliflozin on the Coronary Macrovascular and Microvascular Function in Type 2 Diabetic Patients
Terminated·—·Phase 4·NCT05392959·4 enrolled
Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration
Completed·TThe University of Texas Health Science Center at San Antonio·Phase 4·NCT02911792·72 enrolled
Diabetes Mellitus4 trials
Evaluation and Intervention of Cognitive Function in Patients With Diabetes Mellitus.
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 1·NCT05262257·120 enrolled
Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2
Unknown status·RResearch Clinical Centre of the Russian Railways, JSC·Phase 4·NCT02719756·100 enrolled
Show 1 more trial
SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus
Recruiting·—·Phase 4·NCT06364930·412 enrolled
Acute Myocardial Infarction3 trials
Myocardial Infarction2 trials
Nephrotic Syndrome2 trials
Effect of Dapagliflozin in Non-Diabetic Patients With Nephrotic Syndrome.
Unknown status·—·Phase 4·NCT05966818·90 enrolled
Kidney Disease2 trials
Treatment of Patients With Diabetic Kidney Disease
Unknown status·—·N/A·NCT06187493·70 enrolled
Empagliflozin2 trials
Diabetic Nephropathy2 trials
Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy
Not yet recruiting·—··NCT06668753·114 enrolled
Huangqi Guizhi Wuwu Decoction in CKD Stage 2-4 Diabetic Nephropathy
Unknown status·TThe First Affiliated Hospital of Dalian Medical University·N/A·NCT05418465·100 enrolled
Mitral regurgitation2 trials
Lupus Nephritis2 trials
Dapagliflozin in Active Lupus Nephritis
Not yet recruiting·—·Phase 4·NCT07323524·33 enrolled
Obesity2 trials
Clinical Trial2 trials
Peripheral Neuropathy1 trial
Efficacy of Dapagliflozin in Diabetes Associated Peripheral Neuropathy
Unknown status·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 2/3·NCT05162690·40 enrolled
Cardiovascular Disease1 trial
Lung Adenocarcinoma1 trial
Calcification1 trial
Trial1 trial
Cardiovascular1 trial
Combination Therapy1 trial
Safety and Efficacy1 trial
Assessment of Safety and Efficacy of SGLT2is Among LN Patients
Unknown status·—·Phase 1/2·NCT06113900·50 enrolled
Proteinuria1 trial
Efficacy and Safety of Dapagliflozin in Children With Proteinuria
Active, not recruiting·—·N/A·NCT07204743·10 enrolled
Ascites1 trial
Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT
Unknown status·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 2·NCT05014594·44 enrolled
Insulin resistance1 trial
Efficacy and Safety1 trial
Hypertension1 trial
Endothelial Function1 trial
Effect of Dapagliflozin on Inflammation and Endothelial Function
Terminated·—·Phase 4·NCT02608905·17 enrolled
Breast Cancer1 trial
CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL
Recruiting·—·Phase 3·NCT06304857·188 enrolled
Acute Coronary Syndrome1 trial
Blood Pressure1 trial
Peritoneal Dialysis1 trial
Chronic Obstructive Pulmonary Disease1 trial
Left Ventricular Hypertrophy1 trial
Pancreatic Cancer1 trial
Refractory Solid Tumors1 trial
Exercise Training1 trial
Polycystic Ovary Syndrome1 trial
Overweight1 trial
Effects of Liraglutid, Dapagliflozin and Acarbose on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in Overweight/Obese T2DM Patients Controlled Inadequately With Metformin Monotherapy.
Unknown status·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·N/A·NCT03961659·87 enrolled
COVID-191 trial
mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms
Completed·—·Phase 2/3·NCT04393246·454 enrolled
Oral1 trial
Impaired glucose tolerance1 trial
Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)
Recruiting·TThe University of Texas Health Science Center at San Antonio·N/A·NCT02969798·700 enrolled
End-Stage Renal Disease1 trial
Efficacy1 trial
Physical Activity1 trial
Drug1 trial
Cognitive Protective Effect of Newer Antidiabetic Drugs
Unknown status·—··NCT05347459·100 enrolled
Myocardial fibrosis1 trial
Unspecified3 trials
Regulatory
FDA Approval Timeline[5]
Jan 8, 2014
FARXIGA
NDA NDA202293
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Farxiga drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Dapagliflozin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
- [8]
Details
Drug Info
Quick Facts
- Mechanism of Action
- SGLT2 Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
Patent Landscape[6]
Patent Cliff
Aug 18, 2026
Earliest patent expiration — generic entry possible after this date
Patent #Expires
8906851Aug 18, 2026
8329648Aug 18, 2026
8361972Mar 21, 2028
7851502Aug 19, 2028
8716251*PEDSep 21, 2028
17 more patents
8221786*PEDSep 21, 2028
7851502*PEDFeb 19, 2029
8721615Jan 18, 2030
8685934May 26, 2030
8721615*PEDJul 18, 2030
11826376Jul 18, 2039
12472194Jul 18, 2039
11826376*PEDJan 18, 2040
12472194*PEDJan 18, 2040
11903955Mar 9, 2040
10973836Mar 9, 2040
11903955*PEDSep 9, 2040
10973836*PEDSep 9, 2040
12213988Apr 1, 2041
12409186Apr 1, 2041
12409186*PEDOct 1, 2041
12213988*PEDOct 1, 2041